Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACXP logo ACXP
Upturn stock ratingUpturn stock rating
ACXP logo

Acurx Pharmaceuticals LLC (ACXP)

Upturn stock ratingUpturn stock rating
$4.77
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ACXP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $61.7

1 Year Target Price $61.7

Analysts Price Target For last 52 week
$61.7 Target price
52w Low $3.8
Current$4.77
52w High $44.9

Analysis of Past Performance

Type Stock
Historic Profit -27.77%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.72M USD
Price to earnings Ratio -
1Y Target Price 61.7
Price to earnings Ratio -
1Y Target Price 61.7
Volume (30-day avg) 3
Beta -1.26
52 Weeks Range 3.80 - 44.90
Updated Date 08/28/2025
52 Weeks Range 3.80 - 44.90
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -10.57

Earnings Date

Report Date 2025-08-12
When -
Estimate -0.18
Actual -1.89

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -98.59%
Return on Equity (TTM) -285.94%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1653726
Price to Sales(TTM) -
Enterprise Value 1653726
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.54
Shares Outstanding 1584780
Shares Floating 1311702
Shares Outstanding 1584780
Shares Floating 1311702
Percent Insiders 8.12
Percent Institutions 13.95

ai summary icon Upturn AI SWOT

Acurx Pharmaceuticals LLC

stock logo

Company Overview

overview logo History and Background

Acurx Pharmaceuticals, LLC is a biopharmaceutical company focused on developing new antibiotics for difficult-to-treat infections. It focuses on developing and commercializing innovative technologies for the prevention and treatment of infectious diseases.

business area logo Core Business Areas

  • Infectious Disease Therapeutics: Focused on developing antibiotics that address unmet needs in the treatment of bacterial infections, particularly C. difficile infections (CDI).

leadership logo Leadership and Structure

Acurx is led by a management team with experience in drug development and commercialization. The specific details of the organizational structure and complete leadership team may be found on their investor relations page.

Top Products and Market Share

overview logo Key Offerings

  • Ibezapolstat: A novel, orally administered, investigational agent being developed for the treatment of Clostridioides difficile infection (CDI). It is designed to selectively target C. difficile in the gut while sparing other beneficial bacteria. As this is still in development, there is no market share yet. Competitors in the CDI market include Merck (VZIO) with Dificid and Seres Therapeutics (MCRB) with VOWST.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically the antibiotics market, is characterized by high R&D costs, stringent regulatory requirements, and increasing antibiotic resistance. The market for CDI therapeutics is substantial and growing, driven by aging populations and increased healthcare-associated infections.

Positioning

Acurx is positioned as an innovator in the field of microbiome-sparing antibiotics, with Ibezapolstat representing a potentially differentiated approach to CDI treatment.

Total Addressable Market (TAM)

The global Clostridium difficile infection treatment market size was valued at $1.8 billion in 2023 and is expected to reach $2.8 billion by 2032, according to Allied Market Research. Acurx is positioned to capture a portion of this TAM with successful Ibezapolstat commercialization.

Upturn SWOT Analysis

Strengths

  • Novel microbiome-sparing approach
  • Potential for improved CDI treatment outcomes
  • Strong intellectual property position

Weaknesses

  • Reliance on a single lead product (Ibezapolstat)
  • Clinical trial and regulatory risks
  • Limited commercial infrastructure

Opportunities

  • Expansion into other infectious disease indications
  • Partnerships with larger pharmaceutical companies
  • Growing awareness of microbiome-sparing antibiotics

Threats

  • Competition from established CDI treatments
  • Changes in regulatory landscape
  • Failure to achieve clinical trial success

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • MCRB

Competitive Landscape

Acurx's advantage lies in its novel microbiome-sparing approach, but it faces competition from established therapies like Dificid (Merck) and VOWST (Seres). Success depends on demonstrating superior efficacy and safety in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily reflected in the progression of Ibezapolstat through clinical trials and the associated market capitalization changes.

Future Projections: Future growth depends heavily on the successful completion of clinical trials, regulatory approval, and subsequent commercialization of Ibezapolstat. Analyst estimates aren't widely available due to the early stage nature of the company.

Recent Initiatives: Recent initiatives focus on advancing Ibezapolstat through Phase 3 clinical trials and exploring potential partnerships.

Summary

Acurx Pharmaceuticals is a development-stage company with a focus on microbiome-sparing antibiotics, particularly Ibezapolstat for CDI. Its success is contingent on clinical trial outcomes and regulatory approval, making it a high-risk, high-reward investment. The company's novel approach offers potential differentiation, but it faces competition from established players. Continued clinical progress and strategic partnerships are critical for its future growth. Investors should monitor clinical trial results and cash runway closely.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC filings
  • Industry reports
  • Company website
  • Allied Market Research reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Acurx Pharmaceuticals LLC

Exchange NASDAQ
Headquaters Staten Island, NY, United States
IPO Launch date 2021-06-25
Co-Founder, President, CEO, Corporate Secretary & Director Mr. David P. Luci CPA, Esq., J.D.
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.